【Molcure Inc. 】 MOLCURE signs joint research agreement with Teijin Pharma to develop antibody drugs using AI-driven drug discovery platform technology

2025.01.09

MOLCURE Inc. announced that it has signed a joint research agreement with Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business. This agreement aims to use MOLCURE’s AI-driven drug discovery platform technology to develop innovative antibody drugs for central nervous system diseases.

◆Click the link below for more details.
MOLCURE signs joint research agreement with Teijin Pharma to develop antibody drugs using AI-driven drug discovery platform technology